Benitec

Benitec

Benitec

Silencing Genes for Life: Benitec is developing novel treatments for chronic & life-threatening conditions via ddRNAi. Publicly Listed NASDAQ:BNTC and ASX:BLT
Type
B2c
Raised
$5.5M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$5,450,000
Post-IPO equity - 2017
NantCapital
Team Size
1–10
Employees
Location
Headquarters
$5,450,000 Post-IPO equity
GEN

$4.1M Nant Investment in Benitec Supports Joint Antisense RNA Program for HNSCC Genetic Engineering & Biotechnology News...